Anti-aging comes down to chemicals made in your body, instead of those found on store shelves In a nutshell Hormones like IGF ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

The awards program honors individuals who have significantly amplified the voices of Latina/o students at the U of A and have shown a deep dedication to equity and inclusion within the student body.

"They always get a bad rap, but here we have some positive results for prunes," Dr. Mary Jane De Souza said.

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

Recently postmenopausal women with elevated blood pressure but no other CVD risk factors were more likely to develop white matter lesions 14 years later, regardless of short-term hormone therapy use, ...

Calcitonin salmon injection is used to treat Paget’s disease, hypercalcemia and postmenopausal osteoporosis.

New research links early menopause and shorter reproductive years to a higher risk of ACPA-negative inflammatory arthritis in postmenopausal women, suggesting a critical role for oestrogen in ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

In addition, the FDA granted a provisional determination for both Ospomyv and Xbryk's interchangeability designation. OSPOMYV, referencing Prolia, has been approved for the treatment of postmenopausal ...

OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ...